INmune Bio Inc. - Common stock (NQ:INMB)

1.790 +0.040 (+2.29%)

Streaming Delayed Price Updated: 1:19 PM EDT, Aug 3, 2026 Add to My Watchlist

Price and Volume

Volume	119,347
Open	1.770
Bid (Size)	1.780 (3,000)
Ask (Size)	1.790 (1,400)
Prev. Close	1.750
Today's Range	1.720 - 1.830
52wk Range	1.090 - 2.960
Shares Outstanding	17,703,692
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

INmune Bio Receives R&D Rebates of Approximately $4.6 Million

July 31, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th

July 31, 2026

From INmune Bio, Inc.

Via GlobeNewswire

Performance

YTD	+16.2%	+16.2%
1 Month	+7.5%	+7.5%
3 Month	+20.9%	+20.9%
6 Month	+13.3%	+13.3%
1 Year	-37.3%	-37.3%

More News

INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform

July 30, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform

July 20, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study

July 15, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INMUNE BIO INC (NASDAQ:INMB) Beats Q1 2026 EPS Estimates as Stock Shows Recent Momentum ↗

May 07, 2026

Via Chartmill

INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial? ↗

February 12, 2026

Via Stocktwits

INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC

July 09, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion

July 01, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™

June 25, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB

June 23, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial

June 02, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio (INMB) Q4 2025 Earnings Transcript ↗

June 01, 2026

Via The Motley Fool

INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform

May 15, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease

May 14, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point

May 13, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio (INMB) Q1 2026 Earnings Transcript ↗

May 08, 2026

Via The Motley Fool

INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases

May 05, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th

April 30, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models

April 16, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.

March 24, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease

March 19, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar

February 23, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB

February 19, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease

February 12, 2026

From INmune Bio, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is INmune Bio Inc. - Common stock publicly traded?

Yes, INmune Bio Inc. - Common stock is publicly traded.

What exchange does INmune Bio Inc. - Common stock trade on?

INmune Bio Inc. - Common stock trades on the Nasdaq Stock Market

What is the ticker symbol for INmune Bio Inc. - Common stock?

The ticker symbol for INmune Bio Inc. - Common stock is INMB on the Nasdaq Stock Market

What is the current price of INmune Bio Inc. - Common stock?

The current price of INmune Bio Inc. - Common stock is 1.790

When was INmune Bio Inc. - Common stock last traded?

The last trade of INmune Bio Inc. - Common stock was at 08/03/26 01:19 PM ET

What is the market capitalization of INmune Bio Inc. - Common stock?

The market capitalization of INmune Bio Inc. - Common stock is 31.69M

How many shares of INmune Bio Inc. - Common stock are outstanding?

INmune Bio Inc. - Common stock has 32M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.